Atherosclerosis

1989

DOI: 10.1016/0021-9150(89)90157-3

|View full text |Cite

|

Sign up to set email alerts

|

Ganglioside content and composition of cells from normal and atherosclerotic human aorta

Dmitry N. Mukhin

¹

,

N. V. Prokazova

²

,

L. D. Bergel'son

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Endogenous Immune Response To Gangliosides1

Possible Contribution Of Gm2 Activator Protein To Atherogenesis1

Histologic Findings and Histometric Results1

Sphingolipids As Promoters Of Atherosclerosis1

Citation Types

Supporting

1

Mentioning

11

Contrasting

0

Year Published

1990

1990

2007

2007

Publication Types

Select...

Article8

Book1

Relationship

Self Cite0

Independent9

Authors

Journals

Cited by 23 publications

(12 citation statements)

References 23 publications

Supporting

1

Mentioning

11

Contrasting

0

Order By: Relevance

“…It is also found in normal tissue. 4,[58][59][60][61][62][63] Despite this lack of specificity, GD1a appears to be immunogenic. Kanda and Watanabe 64 showed that GD1a greatly enhanced spontaneous IgM production by human peripheral blood mononuclear cells (PBMC) in vitro, without affecting proliferation or viability of PBMC; however, exposure of isolated B cells alone to GD1a did not alter IgM production.…”

Section: Endogenous Immune Response To Gangliosidesmentioning

confidence: 99%

Endogenous immune response to gangliosides in patients with confined prostate cancer

¹

,

²

,

³

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Our study investigated whether endogenous IgM antibodies to gangliosides occur in patients with early stages of prostate cancer (CaP) patients, after defining ganglioside profiles of CaP cell lines. Immune and resorcinol staining detected the presence of gangliosides GM3, GM2, GD3, GD2 and GD1a but not GM1a, GD1b or GT1b in the extracts of normal prostatic epithelial cells (PrEC) and neoplastic androgen‐insensitive (PC‐3, DU145) and ‐sensitive (LNCaP‐FGC and LNCaP‐FGC‐10) CaP cells. Using a sensitive ELISA, developed and validated in our laboratory, the titers of IgM against 8 gangliosides from sera of patients with benign prostatic hyperplasia (BPH) (n = 11), organ‐confined (T1/T2, n = 36) and unconfined (T3/T4, n = 27) CaP and age‐matched healthy men (n = 11) were determined double‐blinded. Using ANOVA and Fisher's least significant difference (LSD) methods, the log‐titers among different groups were compared. CaP patients differed from healthy and BPH patients in increased titers against GD1a and decreased titers against GD3. Titers of antibodies to other gangliosides exhibited no difference between CaP patients and others. The specific augmentation of anti‐GD1a IgM in patients with organ‐confined CaP (stage T1/T2) but not in patients with unconfined CaP (stage T3/T4) or BPH or in healthy controls is striking. This finding together with identification of GD1a as a major ganglioside in CaP cell lines and with the accruing studies on the immunosuppressive nature of GD1a indicates that augmentation of anti‐GD1a IgM in confined CaP may signify an early endogenous immune response to eliminate a “danger signal” from tumor microenvironment and circulation. © 2005 Wiley‐Liss, Inc.

“…It is also found in normal tissue. 4,[58][59][60][61][62][63] Despite this lack of specificity, GD1a appears to be immunogenic. Kanda and Watanabe 64 showed that GD1a greatly enhanced spontaneous IgM production by human peripheral blood mononuclear cells (PBMC) in vitro, without affecting proliferation or viability of PBMC; however, exposure of isolated B cells alone to GD1a did not alter IgM production.…”

Section: Endogenous Immune Response To Gangliosidesmentioning

confidence: 99%

Endogenous immune response to gangliosides in patients with confined prostate cancer

¹

,

²

,

³

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Our study investigated whether endogenous IgM antibodies to gangliosides occur in patients with early stages of prostate cancer (CaP) patients, after defining ganglioside profiles of CaP cell lines. Immune and resorcinol staining detected the presence of gangliosides GM3, GM2, GD3, GD2 and GD1a but not GM1a, GD1b or GT1b in the extracts of normal prostatic epithelial cells (PrEC) and neoplastic androgen‐insensitive (PC‐3, DU145) and ‐sensitive (LNCaP‐FGC and LNCaP‐FGC‐10) CaP cells. Using a sensitive ELISA, developed and validated in our laboratory, the titers of IgM against 8 gangliosides from sera of patients with benign prostatic hyperplasia (BPH) (n = 11), organ‐confined (T1/T2, n = 36) and unconfined (T3/T4, n = 27) CaP and age‐matched healthy men (n = 11) were determined double‐blinded. Using ANOVA and Fisher's least significant difference (LSD) methods, the log‐titers among different groups were compared. CaP patients differed from healthy and BPH patients in increased titers against GD1a and decreased titers against GD3. Titers of antibodies to other gangliosides exhibited no difference between CaP patients and others. The specific augmentation of anti‐GD1a IgM in patients with organ‐confined CaP (stage T1/T2) but not in patients with unconfined CaP (stage T3/T4) or BPH or in healthy controls is striking. This finding together with identification of GD1a as a major ganglioside in CaP cell lines and with the accruing studies on the immunosuppressive nature of GD1a indicates that augmentation of anti‐GD1a IgM in confined CaP may signify an early endogenous immune response to eliminate a “danger signal” from tumor microenvironment and circulation. © 2005 Wiley‐Liss, Inc.

“…1). Ganglioside concentration is remarkably low in isolated cells in contrast to the great number of gangliosides found in whole tissues in the aortic aorta, indicating that higher concentrations may accumulate in the intercellular space 37) . However, it remains unknown how such high concentrations of gangliosides accumulate in the intercellular space.…”

Section: Possible Contribution Of Gm2 Activator Protein To Atherogenesismentioning

confidence: 78%

The Possible Contribution of a General Glycosphingolipid Transporter, GM2 Activator Protein, to Atherosclerosis

¹

,

²

,

³

et al. 2006

J Atheroscler Thromb

View full text Add to dashboard Cite

No abstract

“…Sharon and Lis (1975) have shown that some lectins preferentially agglutinate naturally as well as with chemically transformed cells. Mukhin et al (1989) reported that the alterations in cellular ganglioside content are the result of impaired cellular ganglioside metabolism, synthesis, or degradation.…”

Section: Histologic Findings and Histometric Resultsmentioning

confidence: 99%

Effect of 20-Methylcholanthrene on the Development of Atherosclerosis in LAP Quails.

Sadi¹,

Toda²,

et al. 1994

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

We studied the effect of 20-methylcholanthrene, a carcinogen, on atherosclerosis in the ascending aorta and brachiocephalic arteries of hyperlipidemic and atherosclerosis-prone (LAP) quail . A total of 66 quails were divided into 6 groups and fed the following diets: Group I, basal; Group II, basal + low dose of carcinogen; Group III, basal + high dose of carcinogen; Group IV, basal+0.2% cholesterol; Group V, basal+0.2% cholesterol + low dose of carcinogen; and Group VI, basal + 0.2% of cholesterol + high dose of carcinogen. The carcinogen was dissolved in corn oil at 2 mg/ml and 4 mg/ml as low and high doses respectively, and was given orally twice weekly . Marked elevation of the serum cholesterol level and significant lipid-rich aortic lesions were observed in all the cholesterol-fed groups after 12 weeks. Although the serum cholesterol level in Group VI was lower than that in Group IV , the severity of the atherosclerotic lesion was greater in the former than in the latter. An immunohistochemical study showed a positive reaction of DBA, PHA and OKM-1 with the lipid-containing cells of aortic intimal lesions.carcino-

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.